1.09
0.91%
-0.01
アフターアワーズ:
1.07
-0.02
-1.83%
前日終値:
$1.10
開ける:
$1.06
24時間の取引高:
967.05K
Relative Volume:
0.86
時価総額:
$85.30M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-1.2976
EPS:
-0.84
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-1.80%
1か月 パフォーマンス:
+25.27%
6か月 パフォーマンス:
-14.84%
1年 パフォーマンス:
-18.66%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
1.09 | 85.30M | 101.21M | -569.00K | -56.88M | -0.02 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
2024-05-06 | アップグレード | Jefferies | Hold → Buy |
2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
2021-11-15 | 開始されました | BTIG Research | Buy |
2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
2021-03-29 | 開始されました | JP Morgan | Overweight |
2021-03-23 | アップグレード | Jefferies | Hold → Buy |
2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-20 | 開始されました | Guggenheim | Buy |
2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
2019-03-11 | 開始されました | Barclays | Overweight |
2018-11-26 | 開始されました | Piper Jaffray | Overweight |
2018-10-15 | 開始されました | Goldman | Neutral |
2018-09-13 | 開始されました | H.C. Wainwright | Buy |
2018-06-01 | 開始されました | SunTrust | Buy |
2018-01-05 | 開始されました | Citigroup | Buy |
2017-09-08 | 開始されました | Wedbush | Outperform |
2017-03-27 | 開始されました | H.C. Wainwright | Buy |
2017-03-02 | 開始されました | Instinet | Buy |
2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada
Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat
Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India
Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com
HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World
HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat
CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times
CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks
CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX Therapeutics, Inc.($CTMX) - substack.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
Cytomx Therapeutics Inc (CTMX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
大文字化:
|
ボリューム (24 時間):